To compare the angiographic and clinical outcomes of aggressive versus standard balloon preparation during drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR). The study will evaluate whether more aggressive lesion preparation with cutting/scoring/OPN balloons improves outcomes compared to standard preparation with semi-compliant or non-compliant balloons.
PICCOLETO XI A-PREP is an investigator-initiated, multicenter, international, observational study evaluating the impact of lesion preparation strategies on outcomes following drug-coated balloon (DCB) angioplasty for in-stent restenosis (ISR). In-stent restenosis remains a clinically relevant challenge despite advances in drug-eluting stent technology and contemporary percutaneous coronary intervention techniques. DCB represents a stentless therapeutic strategy for ISR treatment, with the advantage of avoiding implantation of additional metallic layers. A key determinant of clinical outcomes in ISR, particularly with DCB angioplasty, is the adequacy of lesion preparation before definitive therapy. Effective preparation facilitates optimal drug delivery, improves luminal gain, and may reduce the risk of recurrent restenosis. A large spectrum of balloon-based modalities is available for ISR lesion preparation, ranging from semi-compliant and non-compliant balloons to more aggressive tools such as scoring and cutting balloons. Although more aggressive devices may enhance plaque modification and neointimal tissue disruption, their incremental clinical benefit over standard approaches remains uncertain. Patients will be categorized into two groups based on lesion preparation strategy: * Aggressive preparation: Cutting/Wolverine balloons, scoring balloons (any brand), and/or OPN balloons * Standard preparation: Semi-compliant balloons and/or non-compliant balloons Clinical outcomes will be assessed at 1-year and longest available follow-up.
Study Type
OBSERVATIONAL
Enrollment
500
Major Adverse Cardiovascular Events (MACE)
Composite of cardiac death, non-fatal myocardial infarction (MI), or target lesion revascularization (TLR).
Time frame: 12 months
Cardiac Death
Death attributed to cardiovascular causes, including death from unknown cause.
Time frame: 12 months and longest available follow-up
Non-fatal Myocardial Infarction
Non-fatal myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction.
Time frame: 12 months and longest available follow-up
Target Lesion Revascularization (TLR)
Any repeat revascularization (percutaneous or surgical) of the target lesion.
Time frame: 12 months and longest available follow-up
Target Vessel Myocardial Infarction (TV-MI)
Myocardial infarction attributable to the target vessel based on clinical, electrocardiographic, and biomarker criteria.
Time frame: 12 months and longest available follow-up
BARC Major Bleeding
Bleeding Academic Research Consortium (BARC) major bleeding events (type 3-5).
Time frame: 12 months and longest available follow-up
Procedural Success
Successful DCB angioplasty with residual stenosis less than 30% and TIMI flow grade 3 without major procedural complications.
Time frame: At procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Post-procedural Diameter Stenosis
Percentage of diameter stenosis after DCB angioplasty assessed by quantitative coronary angiography.
Time frame: At procedure
Angiographic Dissection
Presence and type of coronary dissection after lesion preparation and DCB treatment.
Time frame: At procedure
TIMI Flow Grade
Thrombolysis In Myocardial Infarction (TIMI) flow grade assessment post-procedure.
Time frame: At procedure